Novartis Ag (NVS) Accounts Payables (2009 - 2026)
Novartis Ag (NVS) posted Accounts Payables of $4.3 billion for Q2 2026, down 4.44% sequentially from $4.5 billion in Q4 2025, and down 5.5% YoY from $4.5 billion in Q2 2025.
Novartis Ag (NVS) Accounts Payables (2009 - 2026) Analysis & Trends
Novartis Ag has reported Accounts Payables for 18 years, with the latest figure at $4.3 billion in Q2 2026.
- Quarterly Accounts Payables fell 5.5% year-over-year to $4.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.3 billion (down 5.5% YoY) and the FY2025 annual result came in at $4.5 billion, up 1600.34% from the prior year.
- Accounts Payables fell to $4.3 billion in Q2 2026 per NVS's latest filing, from $4.5 billion in the prior quarter.
- Over five years, Accounts Payables peaked at $5.4 billion in Q2 2023 and troughed at -$297.0 million in Q4 2024.
- A 5-year average of $2.2 billion and a median of $2.0 billion in 2022 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables plunged 2166.67% in 2022, then surged 7967.65% in 2023.
- Over 5 years, Accounts Payables stood at $5.1 billion in 2022, then sank by 104.49% to -$231.0 million in 2023, then retreated by 28.57% to -$297.0 million in 2024, then jumped by 1600.34% to $4.5 billion in 2025, then slipped by 4.44% to $4.3 billion in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $4.3 billion, $4.5 billion, and $4.5 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 9.22 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 3.83 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 4.58 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -19.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.26 Bn |
| Dec 31, 2025 | 4.46 Bn |
| Jun 30, 2025 | 4.51 Bn |
| Dec 31, 2024 | -297.00 Mn |
| Sep 30, 2024 | -290.00 Mn |
| Jun 30, 2024 | 4.15 Bn |
| Dec 31, 2023 | -231.00 Mn |
| Jun 30, 2023 | 5.35 Bn |
| Dec 31, 2022 | 5.15 Bn |
| Sep 30, 2022 | -68.00 Mn |
| Jun 30, 2022 | -68.00 Mn |
| Mar 31, 2022 | -67.00 Mn |
| Dec 31, 2021 | 5.55 Bn |
| Sep 30, 2021 | -3.00 Mn |
| Jun 30, 2021 | -3.00 Mn |
| Mar 31, 2021 | -3.00 Mn |
| Dec 31, 2020 | -144.00 Mn |
| Sep 30, 2020 | -144.00 Mn |
| Jun 30, 2020 | -144.00 Mn |
| Mar 31, 2020 | -144.00 Mn |